Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com - H.C. Wainwright initiated coverage of Aligos Therapeutics Inc . (NASDAQ:ALGS) with a Buy rating and a $50.00 price target on Monday. The stock, currently trading at $7.70, sits significantly below its 52-week high of $46.80. According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt.
The firm’s coverage is based on the potential of Aligos’ ALG-000184 to become the new standard-of-care for chronic suppression of hepatitis B virus (HBV) and serve as an oral backbone for future functional cure regimens.
H.C. Wainwright highlighted that Aligos’ differentiated capsid assembly modulator (CAM-E) has shown best-in-class monotherapy data, with 100% of patients achieving HBV DNA
The research firm believes ALG-000184 is positioned to replace nucleos(t)ide analogs as the foundation of chronic HBV infection management, citing its clear regulatory path, broad patient applicability, and first-in-class pharmacokinetics.
Beyond HBV, H.C. Wainwright noted Aligos may attract partnerships with ALG-055009, a thyroid hormone receptor-beta agonist with Phase 2a clinical data that supports a potentially best-in-class profile in metabolic dysfunction-associated steatohepatitis (MASH).
In other recent news, Aligos Therapeutics, Inc. has announced the initiation of dosing in the Phase 2 B-SUPREME study of its investigational compound ALG-000184 for chronic hepatitis B virus infection. This randomized, double-blind study will compare ALG-000184 monotherapy with tenofovir disoproxil fumarate in around 200 untreated adult subjects with chronic HBV infection over a period of 48 weeks. The trial aims to evaluate the safety, efficacy, pharmacokinetics, and various biomarkers associated with HBV infection. These developments mark a significant step for Aligos Therapeutics in advancing its research and development efforts. The company has not provided additional updates on its financial performance or analyst ratings at this time. Investors may find the progress in this study noteworthy as it unfolds over the coming months.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.